Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/13/2005 First Published: 1/1/2001


1.		Phase II Study of ESO-1 Peptide Vaccine in HLA-A201 or HLA-DPB104 Positive Patients With Refractory Metastatic Melanoma Expressing ESO-1

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-01-C-0032 NCI-2390, 2390, NCT00020397

Last Modified: 4/13/2007 First Published: 2/20/2004


2.		Phase II Study of Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, ESO-1 Peptide Vaccination Comprising ESO-1:157-165 (165V) Peptide and Montanide ISA-51, and Interleukin-2 in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-04-C-0104 NCI-6233, 6233, NCT00079144


3.		Study of NY-ESO-1 ISCOMATRIX® in Patients With High-Risk, Resected Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				LUD2003-009 NCT00199901

Last Modified: 4/13/2004 First Published: 12/1/2001


4.		Phase I Pilot Study of NY-ESO-1 Peptide Vaccine and Sargramostim (GM-CSF) in Patients With Stage II, III, or IV Soft Tissue Sarcoma Expressing NY-ESO-1 or LAGE Antigen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				CPMC-IRB-13578 LUDWIG-LUD00-024, NCI-G01-2035, NCT00027911

Last Modified: 5/12/2004 First Published: 5/1/2002


5.		Phase I Pilot Randomized Study of Melanoma Peptide Vaccine With or Without Sargramostim (GM-CSF) in Patients With High-Risk or Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				CPMC-IRB-13824 LUDWIG-LUD00-025, NCI-G02-2068, NCT00037037

Last Modified: 4/6/2006 First Published: 7/26/2003


6.		Phase I Study of NY-ESO-1b Peptide Vaccine and Montanide ISA-51 in Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Expressing NY-ESO-1 or LAGE-1

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				MSKCC-03034 LUDWIG-LUD2002-014, NCT00066729

Last Modified: 4/6/2006 First Published: 9/24/2003


7.		Phase I Pilot Study of NY-ESO-1 Peptide Vaccine, BCG, and Sargramostim (GM-CSF) in Post-Cystectomy Patients With Transitional Cell Carcinoma of the Bladder Expressing NY-ESO-1 or LAGE-1 Antigen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				MSKCC-03047 LUDWIG-LUD2002-004, NCT00070070


8.		Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Other				LUD2002-005 NCT00106158


9.		NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Other				NYU 04-53, LUD2004-006 NCT00142454


10.		NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				Other				LUD2003-022;NYU05-120;CUMC9147 NCT00299728

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute